Bill Sibold, Madrigal Pharmaceuticals

from Being a Life Sciences Leader · host Life Sciences Pennsylvania

Send us Fan MailTune in and learn about the $660 million public offering Madrigal Pharmaceuticals received to deliver novel therapeutics for nonalcoholic steatohepatitis (NASH). Hear from Bill Sibold as he shares his experience leading one of the year's most significant biotech fundraisings, the preparations and strategies behind the raise and how this milestone positions Madrigal to bring innovative treatments to patients.

Episode metadata supplied by the publisher feed · Published Apr 29, 2025

Embed this episode

Attribution link and audio player

Ready to play

Bill Sibold, Madrigal Pharmaceuticals

0:00 31:00

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Being a Life Sciences Leader?

This episode is 31 minutes long.

When was this Being a Life Sciences Leader episode published?

This episode was published on April 29, 2025.

Can I download this Being a Life Sciences Leader episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!